To further demonstrate that SQLE exerts pro-tumor effects via the P53 signaling pathway and the PTEN/AKT/GSK3β signaling pathway, we first selected PFT-β hydrobromide (PFT-β), an inhibitor of the p53 protein, for rescue experiments. This evidence concerns the gene AKT1 and neoplasm.